role of lapatinib in her2-positive breast cancer
Published 10 years ago • 2.6K plays • Length 13:18Download video MP4
Download video MP3
Similar videos
-
9:38
role of t-dm1 in her2-positive metastatic breast cancer
-
5:01
neoadjuvant lapatinib in her2 early breast cancer
-
5:29
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
2:36
dr. blackwell discusses tucatinib in her2 breast cancer
-
2:39
ma.31 trial: taxane with lapatinib or trastuzumab in first-line metastatic breast cancer
-
5:21
study of neratinib for patients with her2-positive breast cancer with brain metastases
-
2:00
a study of brain radiotherapy with lapatinib in her2 breast cancer
-
9:35
neratinib in her2 breast cancer
-
7:31
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
6:08
first-line treatment of her2-positive metastatic breast cancer
-
2:08
dr. jagielska on long-term survival with lapatinib plus capecitabine in her2 breast cancer
-
10:40
inb03 and lapatinib reverses resistance to trastuzumab in her2 breat cancer in pre-clinical models.
-
6:41
the emerging role of neratinib in her2 mbc
-
6:01
treating low-risk her2-positive breast cancer
-
3:52
case study: her2-positive oligometastatic breast cancer
-
3:27
her2 de novo mbc: neratinib vs lapatinib plus capecitabine
-
3:15
neratinib for metastatic breast cancer
-
8:33
pending fda approval of neratinib in her2 breast cancer
-
1:24
dr. yardley on emerging agents in her2-positive breast cancer